Introduction
============

About 5% to 10% of all breast cancers (BCs) are hereditary.[@b1-bic-7-2015-039],[@b2-bic-7-2015-039] Known mutations in the BC susceptibility genes *BRCA1* and *BRCA2* account for more than 50% of hereditary BC.[@b3-bic-7-2015-039] Women who carry a germline mutation in *BRCA1* or *BRCA2* have a 43% to 84% BC risk and a 22% to 39% ovarian cancer (OC) risk by the age of 70 years.[@b4-bic-7-2015-039]--[@b6-bic-7-2015-039]

The majority (90%)[@b7-bic-7-2015-039] of lesions that occur in the breast are benign. Benign breast diseases (BBDs) become more common during the second decade of life and peak during the fourth and fifth decades; incidence of malignant disease, however, continues to rise after menopause.[@b8-bic-7-2015-039]--[@b10-bic-7-2015-039] Family history (FH) of BC,[@b11-bic-7-2015-039],[@b12-bic-7-2015-039] obesity,[@b13-bic-7-2015-039] fibroglandular breast tissue density of at least 25%,[@b14-bic-7-2015-039] and estrogen-receptor (ER) expression in epithelial hyperplasia lacking atypia and in adjacent normal lobules[@b15-bic-7-2015-039] have been identified as risk factors for BBDs.

BBDs include a spectrum of lesions ranging from developmental abnormalities, inflammatory lesions, and epithelial and stromal proliferations to various neoplasms.[@b16-bic-7-2015-039] Fibroadenoma and fibrocystic changes are the two most common BBDs.[@b13-bic-7-2015-039],[@b17-bic-7-2015-039],[@b18-bic-7-2015-039] Although nonproliferative disease does not appear to be associated with increased BC risk,[@b19-bic-7-2015-039] proliferative disease without atypia and that with atypia (ductal carcinoma in situ, atypical hyperplasia, and sclerosing adenosis) have been associated with a 1.5- to 4-fold increased risk for BC, respectively.[@b16-bic-7-2015-039],[@b20-bic-7-2015-039],[@b21-bic-7-2015-039]

Although monitoring may be thorough and frequent, more than 50% of tumors in patients with *BRCA1/2* mutations are identified between screening evaluations (interval carcinomas). It has been postulated that BRCA-associated carcinomas may develop and progress more rapidly than sporadic (nonhereditary) BC.[@b22-bic-7-2015-039],[@b23-bic-7-2015-039] Preneoplastic lesions associated with *BRCA1/2* mutations and sporadic BC are different. Several studies have evaluated histologic features of non-neoplastic breast parenchyma in patients with *BRCA1/2* mutations, but the results are conflicting.[@b24-bic-7-2015-039]--[@b32-bic-7-2015-039] Overall, the limited available data suggest a much higher prevalence of high-risk precursor lesions in BRCA carriers.[@b26-bic-7-2015-039],[@b29-bic-7-2015-039],[@b31-bic-7-2015-039],[@b33-bic-7-2015-039]--[@b35-bic-7-2015-039] Moreover, studies examining histopathologically normal breast parenchyma adjacent to *BRCA*-associated BCs suggest a field effect of genetic changes preceding morphologic changes in the mammary glands.[@b36-bic-7-2015-039]--[@b39-bic-7-2015-039] Loss of heterozygosity (LOH) of the wild-type *BRCA1/2* allele in normal breast epithelial tissue and benign breast lesions was detected in 56% to 81% of *BRCA1/2* carriers with BC.[@b40-bic-7-2015-039],[@b41-bic-7-2015-039] Importantly, LOH was more commonly seen with benign proliferative changes such as sclerosing adenosis, which suggests that these nonmalignant tissues harbor significant amounts of genetic alterations that may predispose to malignant transformation.[@b40-bic-7-2015-039],[@b41-bic-7-2015-039] Cytogenetic abnormalities in prophylactic mastectomy specimens characterized by hyperplasia without atypia in patients with a positive FH of BC (but unknown BRCA status) were also present.[@b42-bic-7-2015-039],[@b43-bic-7-2015-039] It is not known whether benign histopathological changes are related to the BRCA-associated hereditary breast--ovarian cancer spectrum.

This retrospective analysis evaluated histopathologic features of non-neoplastic peritumoral breast parenchyma. The goal was to determine whether there are histopathologic differences in non-neoplastic breast parenchyma in patients with *BRCA1/2* mutation-associated BC and sporadic BC.

Materials and Methods
=====================

Patient population and data collection
--------------------------------------

The prospectively maintained Breast Cancer Management System database at the University of Texas MD Anderson Cancer Center (UTMDACC) identified 181 women with BC who were referred for genetic counseling and underwent genetic testing for *BRCA1* and *BRCA2* gene mutations in 2010 and 2011. All women were physician-referred to the Clinical Cancer Genetics Program at the UTMDACC Breast Center based on a multigenerational FH of BC and/or OC, Ashkenazi Jewish ancestry, or young age (≤50 years). Patients with metastatic BC or those with BRCA mutations that indicated a variant of uncertain significance were excluded from the analysis.

This study was approved by the UTMDACC Institutional Review Board. The retrospective analysis of prospectively collected data included age at the time of BC diagnosis, reproductive history, FH of BC and/or OC, oral contraceptive pill use, hormone replacement therapy (HRT) use, menopausal status at the time of BC diagnosis, previous history of BC, and tumor characteristics.

Pathologic assessment and mutation analysis
-------------------------------------------

All patients underwent definitive surgery either before or after genetic testing, and the pathologic specimens were reviewed by dedicated breast pathologists at UTMDACC. Invasive BC (IBC) was confirmed on initial core biopsy specimens. Histologic type and tumor grade were defined according to the World Health Organization classification system[@b44-bic-7-2015-039] and the modified Black's nuclear grading system,[@b45-bic-7-2015-039] respectively. Immunohistochemical (IHC) analysis was used to determine ER and progesterone-receptor (PR) status. Negative ER and PR status was defined as nuclear staining of 1% or fewer cells on IHC. Human epidermal growth factor receptor-2 (HER2)-negative status was defined as either 2+ or fewer cells or no staining by IHC and/or absence of gene amplification by fluorescence in situ hybridization.

Peritumoral breast parenchyma was reviewed retrospectively for six histological features: benign proliferative breast disease (BPBD) with and without atypia, stromal fibrosis (SF), lobular type (LT), lobular contour (LC), lobular sclerosis (LS), and lobulitis (L). We classified LT based on the predominant pattern as type 1 (\<12 acini), type 2 (\~50 acini), and type 3 (\>50 acini) ([Fig. 1](#f1-bic-7-2015-039){ref-type="fig"}).[@b46-bic-7-2015-039] SF was defined as the presence of dense fibrosis occupying more than 90% of the interlobular stroma[@b47-bic-7-2015-039],[@b48-bic-7-2015-039] and further graded as minimal/absent (grade 1), present (grade 2), or extensive (grade 3) ([Fig. 2](#f2-bic-7-2015-039){ref-type="fig"}). L was defined by the presence of more than 100 lymphocytes and/or plasma cells per lobule and in more than one morphologically normal lobular unit not in relation to periductitis or previous biopsy site changes ([Fig. 3](#f3-bic-7-2015-039){ref-type="fig"}).[@b27-bic-7-2015-039] LC was defined as "regular" if the distinct lobular architecture was preserved with smooth borders in more than half of the non-neoplastic lobules. If the borders of non-neoplastic lobular units showed loss of smooth counters and loss of intralobular stroma in at least 50% of lobules, they were classified as "irregular" LCs ([Fig. 4](#f4-bic-7-2015-039){ref-type="fig"}). LS was defined as the presence of fibrosis identified as expansion of intralobular stroma with distortion of acinar architecture; it was graded as 1 (mild) if sclerosis was identified in fewer than one-third of lobules, 2 (moderate) if sclerosis was present in more than one-third but fewer than two-thirds of lobules, and 3 (extensive) if sclerosis was present in more than two-thirds of lobules.

BRCA testing was performed using germline DNA (from blood) by Myriad Genetics Laboratories, Inc. (Salt Lake City, Utah), and test results were categorized as either positive or negative for a deleterious mutation.

Statistical analysis and outcome measures
-----------------------------------------

Demographic and clinical characteristics were summarized and compared between the three groups and defined by the BRCA status (noncarrier, *BRCA1* carrier, or *BRCA2* carrier), with the chi-square test for categorical variables or the Kruskal--Wallis test for continuous variables. The chi-square test or Fisher's exact test was used to identify the significant factors predictive of a BRCA mutation status. A multivariate logistic regression model was fitted to examine the relationship between BRCA status and benign histological features after adjustment for significant patient and clinical characteristics identified in univariate analyses. *P*-values ≤0.05 were considered statistically significant; all tests were two-sided. Given the small number of *BRCA1* and *BRCA2* cases and the exploratory nature of the study, we report *P*-values without adjusting for multiple testing. Statistical analysis was carried out using SAS 9.2 (SAS Institute Inc.) and S-Plus 8.0 (Insightful Corporation) software.

Results
=======

A total of 181 patients were identified for this analysis; among the subjects, 34% (*n* = 62) were BRCA carriers; 56% (*n* = 35) were found to carry a *BRCA1* mutation, and 44% (*n* = 27) were found to have a *BRCA2* mutation. BRCA mutation prevalence, patient demographics, and clinical characteristics are shown in [Table 1](#t1-bic-7-2015-039){ref-type="table"}. The pathological features of *BRCA1*-associated cases are less favorable than those identified in sporadic cases and cases involving *BRCA2*-associated tumors, with a higher frequency of high-grade, ER/PR-negative or HER2-negative, and TN tumors in this group. BRCA noncarriers were more likely to be premenopausal at the time of diagnosis (*P* = 0.001). In addition, FH of BC (*P* = 0.003), FH of OC (*P* = 0.01), and personal history of BC (*P* = 0.0002) were statistically more common in *BRCA1/2* carriers (38/119 BRCA noncarriers had FH of BC compared to 21/35 *BRCA1* carriers and 15/27 *BRCA2* carriers). Other clinical or demographic characteristics were not significantly different among the three groups. When examining benign histological features, more BRCA noncarriers had SF grade 2/3 tumors than *BRCA1/2* carriers (*P* = 0.04).

Multivariate regression analyses of factors predicting the presence of *BRCA1* or *BRCA2* mutations are shown in [Table 2](#t2-bic-7-2015-039){ref-type="table"}. In the multivariate logistic regression model, TN status (odds ratios \[OR\], 7.29 \[95% CI, 2.60--20.47\]; *P* = 0.002), postmenopausal status at initial diagnosis (OR, 2.83 \[95% CI, 1.05--7.61\]; *P* = 0.04), and nuclear grade 3 (OR, 9.45 \[95% CI, 1.92--46.44\]; *P* = 0.006) remained as independent, significant predictors for a *BRCA1* mutation ([Table 2](#t2-bic-7-2015-039){ref-type="table"}). Patients with a previous BC history (OR, 6.01 \[95% CI, 1.86--19.42\]; *P* = 0.003) or those who were postmenopausal at the time of diagnosis (OR, 3.73 \[95% CI, 1.14--12.25\]; *P* = 0.03) were more likely to have a *BRCA2* mutation ([Table 3](#t3-bic-7-2015-039){ref-type="table"}). No benign histological feature was predictive of a *BRCA1* or *BRCA2* mutation.

Clinicopathologic characteristics of women with BC in relation to each of the six benign peritumoral histologic features were analyzed. Patients with BPBD were older (at least 40 years of age) (*P* = 0.0004) and were more likely to be postmenopausal (*P* = 0.02) than patients without BPBD. BPBD also was more likely to be associated with nuclear grade 1--2 (*P* = 0.02) and PR-positive tumors (*P* = 0.04) ([Table 3](#t3-bic-7-2015-039){ref-type="table"}). Patients with grade 2 SF were younger (*P* = 0.02) and more likely to be premenopausal (*P* = 0.01) than patients with grades 1 or 3 SF ([Table 4](#t4-bic-7-2015-039){ref-type="table"}). Patients with lobular type 2 disease were younger (*P* = 0.0001), more likely to be premenopausal (*P* = 0.0004), had their first pregnancy when they were at least 30 years old (*P* = 0.02), had used HRT for less than 10 years (*P* = 0.009), and had a significantly higher percentage of ER-positive (*P* = 0.05) or PR-positive (*P* = 0.002) tumors than patients with lobular type 1 disease ([Table 5](#t5-bic-7-2015-039){ref-type="table"}). Regular LC was more common in women older than 40 years of age (*P* = 0.04) or postmenopausal women (*P* = 0.003). Women who had their first pregnancy when they were younger than 30 years of age (*P* = 0.048) and had used HRT for at least 10 years (*P* = 0.007) were more likely to have regular LC ([Table 6](#t6-bic-7-2015-039){ref-type="table"}). Grade 1 LS was significantly associated with PR-positive tumors (*P* = 0.03) ([Table 7](#t7-bic-7-2015-039){ref-type="table"}). Lobulitis was more common in women younger than 40 years of age (*P* = 0.004) or premenopausal women (*P* = 0.02), and nuclear grade 3 tumors were less associated with lobulitis (*P* = 0.002) ([Table 8](#t8-bic-7-2015-039){ref-type="table"}).

Discussion
==========

This study investigated whether histopathological features of nonmalignant (peritumoral) breast tissue can help in identifying the risk for BRCA mutation in a selected population of high-risk women with BC. First, we quantitatively assessed the frequencies of the six selected benign histological findings of normal breast tissue of women with BRCA-associated and non-BRCA-associated BC. Although there is a higher incidence of peritumoral grade 2/3 SF in non-BRCA-associated BC than in *BRCA1*- and *BRCA2*-associated BC (71% vs 18% and 11%, respectively \[*P* = 0.04\]), our data indicate that there is no statistically significant association between mutation risk status and the presence of any of the selected benign histologies. Confirming previous studies,[@b6-bic-7-2015-039],[@b34-bic-7-2015-039],[@b49-bic-7-2015-039]--[@b53-bic-7-2015-039] we found that postmenopausal status and TN or nuclear grade 3 BC tumors were independent predictors for *BRCA1* mutations. BC history or postmenopausal status remained independent, significant predictors for a *BRCA2* mutation.

Studies examining peritumoral breast parenchyma have demonstrated histopathological differences between BRCA-associated BCs and non-BRCA-associated BCs. A higher frequency of fibroadenoma[@b54-bic-7-2015-039],[@b55-bic-7-2015-039] and PR expression[@b56-bic-7-2015-039] (*P* = 0.0003) was observed in normal breast epithelium adjacent to IBC in BRCA-linked cases than in sporadic cases. Of note, there was no evidence of allelic loss in normal epithelium either adjacent to or at an unknown distance from the tumor in the latter study.[@b56-bic-7-2015-039] Russo et al[@b57-bic-7-2015-039] demonstrated a preponderance of type 1 lobule over type 3 (48% vs 10%) in women who underwent prophylactic mastectomy because they carried the *BRCA1* gene or belonged to a pedigree with familial BC. Interestingly, Baer and colleagues[@b58-bic-7-2015-039] suggested that women with predominant type 1 and no type 3 lobules who have breasts that likely have undergone more complete involution have a lower BC risk than those with no type 1 lobules or mixed lobule types (OR, 0.63; 95% CI, 0.44--0.91). We did not find any association between LT and higher mutation risk; however, study design may influence the interpretation of data that assessed LT after BC diagnosis (and consequently may not reflect LT prior to BC development).

Mangia et al[@b59-bic-7-2015-039] examined the histopathological features of peritumoral and primary tumor breast tissue to assess mutation risk associated with *BRCA1/2* genes. Among peritumoral lesions, only epithelial proliferative lesions were related to higher mutation risk in patients with familial BC (*P* = 0.003), and a significant difference in terms of high mutation risk was observed in usual ductal hyperplasia lesions (42% high-risk vs 17% low-risk patients; *P* = 0.002). A study conducted by Hermsen et al[@b27-bic-7-2015-039] detected T-cell lobulitis more frequently in prophylactically removed breast tissue from women at hereditary high risk for BC (*N* = 21/41, 51%) compared to controls (*N* = 8/82, 10%) (*P* \< 0.0001). In another study,[@b32-bic-7-2015-039] lobulitis in non-neoplastic breast tissue was independently associated with TN cancers, younger age at diagnosis, and medullary phenotypes---features that are commonly described in hereditary BC. In our study, lobulitis was more common in younger patients; however, we could not demonstrate an association with a specific BC phenotype.

In addition to overall architectural differences, breast tissues in BRCA carriers have histological differences in intralobular and interlobular stroma.[@b57-bic-7-2015-039] Intralobular stroma contrasts with interlobular stroma, which has fewer cells separated by larger quantities of more compact collagen. In our study, BRCA noncarriers had denser interlobular stroma (SF grade 2/3) than BRCA carriers. Our findings are in agreement with those of Mangia et al,[@b59-bic-7-2015-039] which confirm that atrophy and fibrosis are associated with a lower mutation risk. Worsham and colleagues[@b60-bic-7-2015-039] demonstrated that fibrosis was protective against BC; in fact, women with fibrosis were at lower risk for BC progression than women without fibrosis. In contrast, Russo et al[@b57-bic-7-2015-039] found that the intralobular stroma was more fibrotic and dense in women with familial BC than in those with sporadic BC who had mastectomy or women without BC who underwent reduction mammoplasty, which explains in part the increased mammographic density in women with familial BC.[@b61-bic-7-2015-039]

The pathologic characteristics of *BRCA1/2*-related BC (eg, being more often medullary-like, TN, and showing a "basal" phenotype of *BRCA1*-associated BCs) have been taken into account in cancer clinics to help predict which patients may harbor BRCA germline mutations.[@b49-bic-7-2015-039],[@b62-bic-7-2015-039] At present, however, no BC risk model incorporates proliferative lesions without atypia, high breast density, or benign histopathological breast tissue changes into risk calculations.[@b63-bic-7-2015-039]--[@b65-bic-7-2015-039] Our results suggest that no benign histologic feature is associated with BRCA mutation; consequently, there is no reason to regard these features as predictive factors in BRCA models. These findings, however, do not exclude the possibility that molecular or serologic changes may occur without causing a recognizable histologic change that might be used for early detection. If future studies define histopathological features that can be used to predict *BRCA1/2* status, BC risk assessment models may be improved by incorporating the full range of biopsy results into risk calculations. This may have implications for the mutation screening process. Furthermore, studies examining the associations between selected benign histologic findings and normally considered BC-related risk factors may shed light on hereditary BC carcinogenesis models.

This study has several limitations. This analysis was conducted among a small subset of BRCA mutation carriers, which reduced the number of available cases and controls for the analysis and, consequently, the statistical power of the study. Peritumoral benign histological findings may not represent the predominant histology in the rest of the breast, which can lead to some misclassification. However, because the pathologists were blinded to case--control status, any misclassification would be unrelated to outcome.

In summary, our data show that the selected benign histological features of the peritumoral breast parenchyma should not be used as a marker with which to identify patients who are likely to carry mutations in *BRCA1* or *BRCA2* genes. The significance of other benign histological changes in normal breast parenchyma among BRCA carriers without a BC history necessitates further evaluation in larger prospective studies and in other populations. Such investigations may reveal carcinogenic pathways specific to hereditary BC. Enhanced knowledge of these pathways potentially may lead to novel therapeutic targets.
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![The lobular type was classified based on the predominant pattern of lobules. (**A**) An example of type 1 lobule (\<12 acini per lobular unit, ×2). (**B**) An example of type 2 lobule (12--50 acini per lobular unit, ×2). (**C**) An example of type 3 lobule (\>50 acini per lobular unit, ×2).](bic-7-2015-039f1){#f1-bic-7-2015-039}

![Stromal fibrosis is defined as the presence of dense fibrosis of the interlobular stroma. (**A**) An example of a case with minimal fibrosis occupying \<50% of interlobular stroma and graded as grade 1 (×2). (**B**) An example of a case with moderate fibrosis occupying between 90% and 50% interlobular stroma and graded as grade 2 (×2). (**C**) An example of a case with extensive fibrosis occupying \>90% of the interlobular stroma and graded as grade 3 (×2).](bic-7-2015-039f2){#f2-bic-7-2015-039}

![Lobulitis is defined as the presence of \>100 lymphocytes and/or plasma cells per lobule and in more than one morphologically normal lobular unit. (**A**) Lobulitis view at low power showing multiple lobules with lymphoplasmocytic infiltrate (×4). (**B**) Lobulitis view at high power showing lymphoplasmocytic infiltrate (×20).](bic-7-2015-039f3){#f3-bic-7-2015-039}

![Lobular contour is defined as "regular" if the distinct lobular architecture was preserved with smooth borders in more than half of the non-neoplastic lobules. If the borders of lobular units showed loss of smooth contour in at least 50% of lobules, "irregular" lobular contour was classified. (**A**) An example of regular lobular contour (×4). (**B**) An example of irregular lobular contour (×4).](bic-7-2015-039f4){#f4-bic-7-2015-039}

###### 

Association between BRCA positivity, patient demographics, and baseline disease characteristics.

                                                     BRCA NON-CARRIER N = 119 (%)   BRCA1 CARRIER N = 35 (%)   BRCA2 CARRIER N = 27 (%)   *P*
  -------------------------------------------------- ------------------------------ -------------------------- -------------------------- ----------
  Age                                                                                                                                     
   Median (range)                                    43.2 (23.0, 77.9)              44.1 (26.0, 72.5)          47.7 (31.5, 63.5)          
   ≤40                                               46 (71.9%)                     10 (15.6%)                 8 (12.5%)                  0.44
   \>40                                              73 (62.4%)                     25 (21.4%)                 19 (16.2%)                 
  Race                                                                                                                                    
   Black                                             11 (57.9%)                     6 (31.6%)                  2 (10.5%)                  0.70
   White                                             90 (68.2%)                     23 (17.4%)                 19 (14.4%)                 
   Hispanic                                          13 (59.1%)                     5 (22.7%)                  4 (18.2%)                  
   Other                                             5 (62.5%)                      1 (12.5%)                  2 (25%)                    
  Premenopausal at diagnosis                                                                                                              
   No                                                55 (55.6%)                     24 (24.2%)                 20 (20.2%)                 0.001
   Yes                                               61 (80.3%)                     11 (14.5%)                 4 (5.3%)                   
  FH of BC                                                                                                                                
   No                                                80 (75.5%)                     14 (13.2%)                 12 (11.3%)                 0.003
   Yes                                               38 (51.4%)                     21 (28.4%)                 15 (20.3%)                 
  FH of OC                                                                                                                                
   No                                                112 (68.7%)                    28 (17.2%)                 23 (14.1%)                 0.01
   Yes                                               6 (35.3%)                      7 (41.2%)                  4 (23.5%)                  
  Nuclear grade                                                                                                                           
   1--2                                              65 (80.2%)                     4 (4.9%)                   12 (14.8%)                 \<0.0001
   3                                                 54 (54%)                       31 (31%)                   15 (15%)                   
  Histology                                                                                                                               
   Ductal                                            97 (62.6%)                     33 (21.3%)                 25 (16.1%)                 0.11
   Other                                             22 (84.6%)                     2 (7.7%)                   2 (7.7%)                   
  ER status                                                                                                                               
   Negative                                          20 (38.5%)                     26 (50%)                   6 (11.5%)                  \<0.0001
   Positive                                          99 (77.3%)                     8 (6.3%)                   21 (16.4%)                 
  PR status                                                                                                                               
   Negative                                          37 (50%)                       27 (36.5%)                 10 (13.5%)                 \<0.0001
   Positive                                          80 (77.7%)                     6 (5.8%)                   17 (16.5%)                 
  HER2 status                                                                                                                             
   Negative                                          95 (64.2%)                     33 (22.3%)                 20 (13.5%)                 0.01
   Positive                                          20 (83.3%)                     0                          4 (16.7%)                  
  TN status                                                                                                                               
   TN                                                11 (30.6%)                     21 (58.3%)                 4 (11.1%)                  \<0.0001
   Not TN                                            108 (76.1%)                    12 (8.5%)                  22 (15.5%)                 
  Menstrual age                                                                                                                           
   \<12                                              31 (72.1%)                     5 (11.6%)                  7 (16.3%)                  0.42
   ≥12                                               83 (63.8%)                     27 (20.8%)                 20 (15.4%)                 
  Age at first pregnancy                                                                                                                  
   \<30                                              67 (65.7%)                     21 (20.6%)                 14 (13.7%)                 0.55
   ≥30                                               26 (74.3%)                     4 (11.4%)                  5 (14.3%)                  
  N of years of OCP use                                                                                                                   
   \<5                                               43 (66.2%)                     14 (21.5%)                 8 (12.3%)                  0.73
   ≥5                                                71 (69.6%)                     17 (16.7%)                 14 (13.7%)                 
  N of years of HRT use                                                                                                                   
   \<10                                              97 (63.4%)                     34 (22.2%)                 22 (14.4%)                 0.12
   ≥10                                               11 (91.7%)                     0 (0%)                     1 (8.3%)                   
  Previous H of BC                                                                                                                        
   No                                                112 (70.9%)                    28 (17.7%)                 18 (11.4%)                 0.0002
   Yes                                               7 (30.4%)                      7 (30.4%)                  9 (39.1%)                  
  BPBD                                                                                                                                    
   Absent                                            71 (62.8%)                     24 (21.2%)                 18 (15.9%)                 0.56
   Present                                           48 (70.6%)                     11 (16.2%)                 9 (13.2%)                  
  SF                                                                                                                                      
   Grade 1                                           32 (54.2%)                     13 (22%)                   14 (23.7%)                 0.04
   Grades 2, 3                                       87 (71.3%)                     22 (18%)                   13 (10.7%)                 
  LT[a](#tfn1-bic-7-2015-039){ref-type="table-fn"}                                                                                        
   Type 1                                            39 (57.4%)                     18 (26.5%)                 11 (16.2%)                 0.14
   Type 2                                            79 (70.5%)                     17 (15.2%)                 16 (14.3%)                 
  LC                                                                                                                                      
   Regular                                           62 (62%)                       21 (21%)                   17 (17%)                   0.49
   Irregular                                         57 (70.4%)                     14 (17.3%)                 10 (12.3%)                 
  LS                                                                                                                                      
   Grade 1                                           84 (65.6%)                     24 (18.8%)                 20 (15.6%)                 0.80
   Grades 2, 3                                       35 (68.6%)                     10 (19.6%)                 6 (11.8%)                  
  L                                                                                                                                       
   Absent                                            79 (62.2%)                     25 (19.7%)                 23 (18.1%)                 0.64
   Present                                           21 (70%)                       6 (20%)                    3 (10%)                    

**Note:**

No LT type 3 case was detected.

**Abbreviations:** FH, family history; BC, breast cancer; OC, ovarian cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; H, history; OCP, oral contraceptive pill; HRT, hormone replacement therapy; BPBD, benign proliferative breast disease; SF, stromal fibrosis; LT, lobular type; LC, lobular contour; LS, lobular sclerosis; L, lobulitis.

###### 

Multivariate logistic regression model for BRCA1 mutation status.

  EFFECT                                      ODDS RATIO   95% WALD CONFIDENCE LIMITS   *P*-VALUE   
  ------------------------------------------- ------------ ---------------------------- ----------- --------
  *BRCA1*                                                                                           
   MenoStat Postmenopausal vs Premenopausal   2.830        1.052                        7.611       0.04
   TN vs NonTN                                7.289        2.596                        20.470      0.0002
   Nuclear grade 3 vs 1--2                    9.454        1.924                        46.445      0.006
  *BRCA2*                                                                                           
   Prior cancer 1 vs 0                        6.017        1.864                        19.428      0.003
   MenoStat Postmenopausal vs Premenopausal   3.739        1.141                        12.256      0.03

**Abbreviations:** OR, odds ratio; CI, confidence interval; TN, triple-negative.

###### 

Benign proliferative breast disease clinical characteristics and breast tumor histologic findings.

                               ABSENT N(%)   PRESENT N(%)   *P* (UNIVARIATE)
  ---------------------------- ------------- -------------- ------------------
  Age                                                       
   ≤40                         51 (79.7%)    13 (20.3%)     0.0004
   \>40                        62 (53%)      55 (47%)       
  Race                                                      
   Black                       13 (68.4%)    6 (31.6%)      0.86
   White                       80 (60.6%)    52 (39.4%)     
   Hispanic                    14 (63.6%)    8 (36.4%)      
   Other                       6 (75%)       2 (25%)        
  Premenopausal at diagnosis                                
   No                          54 (54.5%)    45 (45.5%)     0.02
   Yes                         55 (72.4%)    21 (27.6%)     
  Nuclear grade                                             
   1--2                        43 (53.1%)    38 (46.9%)     0.02
   3                           70 (70%)      30 (30%)       
  Histology                                                 
   Ductal                      100 (64.5%)   55 (35.5%)     0.15
   Other                       13 (50%)      13 (50%)       
  ER status                                                 
   Negative                    35 (67.3%)    17 (32.7%)     0.36
   Positive                    77 (60.2%)    51 (39.8%)     
  PR status                                                 
   Negative                    52 (70.3%)    22 (29.7%)     0.04
   Positive                    57 (55.3%)    46 (44.7%)     
  HER2 status                                               
   Negative                    90 (60.8%)    58 (39.2%)     0.11
   Positive                    19 (79.2%)    5 (20.8%)      
  TN status                                                 
   TN                          25 (69.4%)    11 (30.6%)     0.32
   Not TN                      86 (60.6%)    56 (39.4%)     
  Menstrual age                                             
   \<12                        26 (60.5%)    17 (39.5%)     0.90
   ≥12                         80 (61.5%)    50 (38.5%)     
  Age at first pregnancy                                    
   \<30                        60 (58.8%)    42 (41.2%)     0.67
   ≥30                         22 (62.9%)    13 (37.1%)     
  N of years of OCP use                                     
   \<5                         41 (63.1%)    24 (36.9%)     0.93
   ≥5                          65 (63.7%)    37 (36.3%)     
  N of years of HRT use                                     
   \<10                        101 (66%)     52 (34%)       0.11
   ≥10                         5 (41.7%)     7 (58.3%)      
  BRCA status                                               
   Negative                    71 (59.7%)    48 (40.3%)     0.56
   BRCA1                       24 (68.6%)    11 (31.4%)     
   BRCA2                       18 (66.7%)    9 (33.3%)      

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; OCP, oral contraceptive pill; HRT, hormone replacement therapy.

###### 

Stromal fibrosis clinical characteristics and breast tumor histologic findings.

                               GRADE 1 N(%)   GRADE 2 N(%)   GRADE 3 N(%)   *P* (UNIVARIATE)
  ---------------------------- -------------- -------------- -------------- ------------------
  Age                                                                       
   ≤40                         13 (20.3%)     35 (54.7%)     16 (25%)       0.02
   \>40                        46 (39.3%)     45 (38.5%)     26 (422.2%)    
  Race                                                                      
   Black                       8 (42.1%)      6 (31.6%)      5 (26.3%)      0.23
   White                       42 (31.8%)     61 (46.2%)     29 (22%)       
   Hispanic                    4 (18.2%)      12 (54.5%)     6 (27.3%)      
   Other                       5 (62.5%)      1 (12.5%)      2 (25%)        
  Premenopausal at diagnosis                                                
   No                          42 (42.4%)     34 (34.3%)     23 (23.2%)     0.01
   Yes                         17 (22.4%)     41 (53.9%)     18 (23.7%)     
  Nuclear grade                                                             
   1--2                        24 (29.6%)     35 (43.2%)     22 (27.2%)     0.49
   3                           35 (35%)       45 (45%)       20 (20%)       
  Histology                                                                 
   Ductal                      53 (34.2%)     68 (43.9%)     34 (21.9%)     0.44
   Other                       6 (23.1%)      12 (46.2%)     8 (30.8%)      
  ER status                                                                 
   Negative                    19 (36.5%)     23 (44.2%)     10 (19.2%)     0.65
   Positive                    40 (31.3%)     56 (43.8%)     32 (25%)       
  PR status                                                                 
   Negative                    24 (32.4%)     33 (44.6%)     17 (23%)       0.97
   Positive                    35 (34%)       45 (43.7%)     23 (22.3%)     
  HER2 status                                                               
   Negative                    48 (32.4%)     64 (43.2%)     36 (24.3%)     0.45
   Positive                    8 (33.3%)      13 (54.2%)     3 (12.5%)      
  TN status                                                                 
   TN                          14 (38.9%)     15 (41.7%)     7 (19.4%)      0.64
   Not TN                      44 (31%)       64 (45.1%)     34 (23.9%)     
  Menstrual age                                                             
   \<12                        19 (44.2%)     18 (41.9%)     6 (14%)        0.11
   ≥12                         38 (29.2%)     58 (44.6%)     34 (26.2%)     
  Age at first pregnancy                                                    
   \<30                        39 (38.2%)     40 (39.2%)     23 (22.5%)     0.35
   ≥30                         9 (25.7%)      18 (51.4%)     8 (22.9%)      
  N of years of OCP use                                                     
   \<5                         21 (32.3%)     30 (46.2%)     14 (21.5%)     0.80
   ≥5                          35 (34.3%)     42 (41.2%)     25 (24.5%)     
  N of years of HRT use                                                     
   \<10                        50 (32.7%)     67 (43.8%)     36 (23.5%)     0.54
   ≥10                         6 (50%)        4 (33.3%)      2 (16.7%)      
  BRCA status                                                               
   Negative                    32 (26.9%)     56 (47.1%)     31 (26.1%)     0.06
   BRCA1                       13 (37.1%)     13 (37.1%)     9 (25.7%)      
   BRCA2                       14 (51.9%)     11 (40.7%)     2 (7.4%)       

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; OCP, oral contraceptive pill; HRT, hormone replacement therapy.

###### 

Lobular type clinical characteristics and breast tumor histologic findings.

                               TYPE 1 N(%)   TYPE 2 N(%)   *P* (UNIVARIATE)
  ---------------------------- ------------- ------------- ------------------
  Age                                                      
   ≤40                         12 (18.8%)    52 (81.3%)    0.0001
   \>40                        56 (48.3%)    60 (51.7%)    
  Race                                                     
   Black                       8 (44.4%)     10 (55.6%)    0.60
   White                       52 (39.4%)    80 (60.6%)    
   Hispanic                    6 (27.3%)     16 (72.7%)    
   Other                       2 (25%)       6 (75%)       
  Premenopausal at diagnosis                               
   No                          49 (50%)      49 (50%)      0.0004
   Yes                         18 (23.7%)    58 (76.3%)    
  Nuclear grade                                            
   1--2                        29 (35.8%)    52 (64.2%)    0.62
   3                           39 (39.4%)    60 (60.6%)    
  Histology                                                
   Ductal                      60 (39%)      94 (61%)      0.42
   Other                       8 (30.8%)     18 (69.2%)    
  ER status                                                
   Negative                    25 (49%)      26 (51%)      0.05
   Positive                    43 (33.6%)    85 (66.4%)    
  PR status                                                
   Negative                    37 (50.7%)    36 (49.3%)    0.002
   Positive                    29 (28.2%)    74 (71.8%)    
  HER2 status                                              
   Negative                    58 (39.5%)    89 (60.5%)    0.17
   Positive                    6 (25%)       18 (75%)      
  TN status                                                
   TN                          20 (57.1%)    15 (42.9%)    0.006
   Not TN                      46 (32.4%)    96 (67.6%)    
  Menstrual age                                            
   \<12                        19 (44.2%)    24 (55.8%)    0.27
   ≥12                         45 (34.9%)    84 (65.1%)    
  Age at first pregnancy                                   
   \<30                        45 (44.6%)    56 (55.4%)    0.02
   ≥30                         8 (22.9%)     27 (77.1%)    
  N of years of OCP use                                    
   \<5                         26 (40%)      39 (60%)      0.48
   ≥5                          35 (34.7%)    66 (65.3%)    
  N of years of HRT use                                    
   \<10                        52 (34.2%)    100 (65.8%)   0.009
   ≥10                         9 (75%)       3 (25%)       
  BRCA status                                              
   Negative                    39 (33.1%)    79 (66.9%)    0.13
   BRCA1                       18 (51.4%)    17 (48.6%)    
   BRCA2                       11 (40.7%)    16 (59.3%)    

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; OCP, oral contraceptive pill; HRT, hormone replacement therapy.

###### 

Lobular contour clinical characteristics and breast tumor histologic findings.

                               REGULAR N(%)   IRREGULAR N(%)   *P* (UNIVARIATE)
  ---------------------------- -------------- ---------------- ------------------
  Age                                                          
   ≤40                         71 (60.7%)     46 (39.3%)       0.04
   \>40                        71 (60.7%)     46 (39.3%)       
  Race                                                         
   Black                       8 (42.1%)      11 (57.9%)       0.67
   White                       75 (56.8%)     57 (43.2%)       
   Hispanic                    12 (54.5%)     10 (45.5%)       
   Other                       5 (62.5%)      3 (37.5%)        
  Premenopausal at diagnosis                                   
   No                          65 (65.7%)     34 (34.3%)       0.003
   Yes                         33 (43.4%)     43 (56.6%)       
  Nuclear grade                                                
   1--2                        48 (59.3%)     33 (40.7%)       0.32
   3                           52 (52%)       48 (48%)         
  Histology                                                    
   Ductal                      87 (56.1%)     68 (43.9%)       0.56
   Other                       13 (50%)       13 (50%)         
  ER status                                                    
   Negative                    30 (57.7%)     22 (42.3%)       0.71
   Positive                    70 (54.7%)     58 (45.3%)       
  PR status                                                    
   Negative                    44 (59.5%)     30 (40.5%)       0.35
   Positive                    54 (52.4%)     49 (47.6%)       
  HER2 status                                                  
   Negative                    85 (57.4%)     63 (42.6%)       0.28
   Positive                    11 (45.8%)     13 (54.2%)       
  TN status                                                    
   TN                          23 (63.9%)     13 (36.1%)       0.23
   Not TN                      75 (52.8%)     67 (47.2%)       
  Menstrual age                                                
   \<12                        28 (65.1%)     15 (34.9%)       0.08
   ≥12                         65 (50%)       65 (50%)         
  Age at first pregnancy                                       
   \<30                        66 (64.7%)     36 (35.3%)       0.048
   ≥30                         16 (45.7%)     19 (54.3%)       
  N of years of OCP use                                        
   \<5                         37 (56.9%)     28 (43.1%)       0.38
   ≥5                          51 (50%)       51 (50%)         
  N of years of HRT use                                        
   \<10                        79 (51.6%)     74 (48.4%)       0.0076
   ≥10                         11 (91.7%)     1 (8.3%)         
  BRCA status                                                  
   Negative                    62 (52.1%)     57 (47.9%)       0.48
   BRCA1                       21 (60%)       14 (40%)         
   BRCA2                       17 (63%)       10 (37%)         

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; OCP, oral contraceptive pill; HRT, hormone replacement therapy.

###### 

Lobular sclerosis clinical characteristics and breast tumor histologic findings.

                               GRADE 1 N(%)   GRADE 2,3 N(%)   *P* (UNIVARIATE)
  ---------------------------- -------------- ---------------- ------------------
  Age                                                          
   ≤40                         44 (69.8%)     19 (30.2%)       0.71
   \>40                        84 (72.4%)     32 (27.6%)       
  Race                                                         
   Black                       15 (78.9%)     4 (21.1%)        0.69
   White                       90 (69.2%)     40 (30.8%)       
   Hispanic                    16 (72.7%)     6 (27.3%)        
   Other                       7 (87.5%)      1 (12.5%)        
  Premenopausal at diagnosis                                   
   No                          69 (71.1%)     28 (28.9%)       0.85
   Yes                         55 (72.4%)     21 (27.6%)       
  Nuclear grade                                                
   1--2                        57 (71.3%)     23 (28.8%)       0.94
   3                           71 (71.7%)     28 (28.3%)       
  Histology                                                    
   Ductal                      113 (73.9%)    40 (26.1%)       0.09
   Other                       15 (57.7%)     11 (42.3%)       
  ER status                                                    
   Negative                    32 (62.7%)     19 (37.3%)       0.10
   Positive                    95 (74.8%)     32 (25.2%)       
  PR status                                                    
   Negative                    46 (63%)       27 (37%)         0.03
   Positive                    79 (77.5%)     23 (22.5%)       
  HER2 status                                                  
   Negative                    104 (71.2%)    42 (28.8%)       0.96
   Positive                    17 (70.8%)     7 (29.2%)        
  TN status                                                    
   TN                          23 (65.7%)     12 (34.3%)       0.43
   Not TN                      102 (72.3%)    39 (27.7%)       
  Menstrual age                                                
   \<12                        33 (78.6%)     9 (21.4%)        0.27
   ≥12                         90 (69.8%)     39 (30.2%)       
  Age at first pregnancy                                       
   \<30                        76 (76%)       24 (24%)         0.38
   ≥30                         24 (68.6%)     11 (31.4%)       
  N of years of OCP use                                        
   \<5                         48 (75%)       16 (25%)         0.35
   ≥5                          69 (68.3%)     32 (31.7%)       
  N of years of HRT use                                        
   \<10                        107 (70.9%)    44 (29.1%)       1.00
   ≥10                         9 (75%)        3 (25%)          
  BRCA status                                                  
   Negative                    84 (70.6%)     35 (29.4%)       0.80
   BRCA1                       24 (70.6%)     10 (29.4%)       
   BRCA2                       20 (76.9%)     6 (23.1%)        

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; OCP, oral contraceptive pill; HRT, hormone replacement therapy.

###### 

Lobulitis clinical characteristics and breast tumor histologic findings.

                               ABSENT N(%)   PRESENT N(%)   *P* (UNIVARIATE)
  ---------------------------- ------------- -------------- ------------------
  Age                                                       
   ≤40                         37 (68.5%)    17 (31.5%)     0.004
   \>40                        90 (87.4%)    13 (12.6%)     
  Race                                                      
   Black                       14 (82.4%)    3 (17.6%)      0.25
   White                       93 (81.6%)    21 (18.4%)     
   Hispanic                    12 (66.7%)    6 (33.3%)      
   Other                       8 (100%)      0 (0%)         
  Premenopausal at diagnosis                                
   No                          77 (87.5%)    11 (12.5%)     0.02
   Yes                         47 (73.4%)    17 (26.6%)     
  Nuclear grade                                             
   1--2                        64 (91.4%)    6 (8.6%)       0.002
   3                           63 (72.4%)    24 (27.6%)     
  Histology                                                 
   Ductal                      107 (79.9%)   27 (20.1%)     0.57
   Other                       20 (87%)      3 (13%)        
  ER status                                                 
   Negative                    40 (87%)      6 (13%)        0.21
   Positive                    87 (78.4%)    24 (21.6%)     
  PR status                                                 
   Negative                    54 (83.1%)    11 (16.9%)     0.49
   Positive                    70 (78.7%)    19 (21.3%)     
  HER2 status                                               
   Negative                    105 (81.4%)   24 (18.6%)     0.55
   Positive                    16 (76.2%)    5 (23.8%)      
  TN status                                                 
   TN                          28 (87.5%)    4 (12.5%)      0.32
   Not TN                      97 (78.9%)    26 (21.1%)     
  Menstrual age                                             
   \<12                        30 (75%)      10 (25%)       0.28
   ≥12                         91 (82.7%)    19 (17.3%)     
  Age at first pregnancy                                    
   \<30                        73 (80.2%)    18 (19.8%)     0.17
   ≥30                         19 (67.9%)    9 (32.1%)      
  N of years of OCP use                                     
   \<5                         41 (78.8%)    11 (21.2%)     0.91
   ≥5                          74 (79.6%)    19 (20.4%)     
  N of years of HRT use                                     
   \<10                        104 (78.2%)   29 (21.8%)     0.21
   ≥10                         10 (100%)     0 (0%)         
  BRCA status                                               
   Negative                    79 (79%)      21 (21%)       0.64
   BRCA1                       25 (80.6%)    6 (19.4%)      
   BRCA2                       23 (88.5%)    3 (11.5%)      

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; N, number; OCP, oral contraceptive pill; HRT, hormone replacement therapy.
